Cargando…
Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX
Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750610/ https://www.ncbi.nlm.nih.gov/pubmed/36626539 http://dx.doi.org/10.1097/MD.0000000000032150 |
_version_ | 1784850293532393472 |
---|---|
author | Yoshikawa-Kimura, Akie Taira, Koichi Maruyama, Hirotsugu Ishikawa-Kakiya, Yuki Yamamura, Masafumi Tanoue, Kojiro Hagihara, Atsushi Uchida-Kobayashi, Sawako Enomoto, Masaru Kimura, Kenjiro Tanaka, Shogo Amano, Ryosuke Takemura, Shigekazu Ohfuji, Satoko Tanaka, Fumio Nagami, Yasuaki Fujiwara, Yasuhiro |
author_facet | Yoshikawa-Kimura, Akie Taira, Koichi Maruyama, Hirotsugu Ishikawa-Kakiya, Yuki Yamamura, Masafumi Tanoue, Kojiro Hagihara, Atsushi Uchida-Kobayashi, Sawako Enomoto, Masaru Kimura, Kenjiro Tanaka, Shogo Amano, Ryosuke Takemura, Shigekazu Ohfuji, Satoko Tanaka, Fumio Nagami, Yasuaki Fujiwara, Yasuhiro |
author_sort | Yoshikawa-Kimura, Akie |
collection | PubMed |
description | Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survival. Thus, we aimed to elucidate the effects of biliary stents on the survival of patients with advanced pancreatic cancer treated with modified FOLFIRINOX (mFFX). We retrospectively reviewed medical charts of patients with advanced pancreatic cancer treated with mFFX between January 2014 and April 2020. We compared the overall survival (OS) of patients with and without biliary stent during mFFX treatment and examined the independent effect on mortality using propensity score matching. Overall, we included 89 patients (stent group, n = 24; non-stent group, n = 65). The proportion of patients with pancreatic head cancer was significantly higher in the stent group than in the non-stent group (P < .01). Stratification analysis in patients with pancreatic head cancer revealed that OS was significantly shorter in the stent group than in the non-stent group (P = .03). After propensity score matching, 19 pairs of patients in each group were analyzed. The stent group revealed a significantly shorter survival than the non-stent group (median OS, 10.3 vs 24.9 months; P < .01). The incidences of febrile neutropenia (P = .01) and biliary tract-related events that required biliary stenting or stent replacement (P < .01) were significantly higher in the stent group than in the non-stent group. Stent insertion was an independent risk factor for overall mortality. Biliary stents may reduce survival in patients with advanced pancreatic cancer. The rate of febrile neutropenia was higher in the stent group than in the non-stent group. There is a need to assess the patient’s condition with discretion and develop a treatment strategy with short prognosis in mind after stent insertion. |
format | Online Article Text |
id | pubmed-9750610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-97506102022-12-28 Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX Yoshikawa-Kimura, Akie Taira, Koichi Maruyama, Hirotsugu Ishikawa-Kakiya, Yuki Yamamura, Masafumi Tanoue, Kojiro Hagihara, Atsushi Uchida-Kobayashi, Sawako Enomoto, Masaru Kimura, Kenjiro Tanaka, Shogo Amano, Ryosuke Takemura, Shigekazu Ohfuji, Satoko Tanaka, Fumio Nagami, Yasuaki Fujiwara, Yasuhiro Medicine (Baltimore) 4500 Endoscopic biliary drainage is the recommended 1(st)-line treatment for malignant biliary obstruction. Although a high incidence of febrile neutropenia has been reported in patients treated with FOLFIRINOX and a biliary stent, it remains unknown whether the biliary stent contributes to patient survival. Thus, we aimed to elucidate the effects of biliary stents on the survival of patients with advanced pancreatic cancer treated with modified FOLFIRINOX (mFFX). We retrospectively reviewed medical charts of patients with advanced pancreatic cancer treated with mFFX between January 2014 and April 2020. We compared the overall survival (OS) of patients with and without biliary stent during mFFX treatment and examined the independent effect on mortality using propensity score matching. Overall, we included 89 patients (stent group, n = 24; non-stent group, n = 65). The proportion of patients with pancreatic head cancer was significantly higher in the stent group than in the non-stent group (P < .01). Stratification analysis in patients with pancreatic head cancer revealed that OS was significantly shorter in the stent group than in the non-stent group (P = .03). After propensity score matching, 19 pairs of patients in each group were analyzed. The stent group revealed a significantly shorter survival than the non-stent group (median OS, 10.3 vs 24.9 months; P < .01). The incidences of febrile neutropenia (P = .01) and biliary tract-related events that required biliary stenting or stent replacement (P < .01) were significantly higher in the stent group than in the non-stent group. Stent insertion was an independent risk factor for overall mortality. Biliary stents may reduce survival in patients with advanced pancreatic cancer. The rate of febrile neutropenia was higher in the stent group than in the non-stent group. There is a need to assess the patient’s condition with discretion and develop a treatment strategy with short prognosis in mind after stent insertion. Lippincott Williams & Wilkins 2022-12-09 /pmc/articles/PMC9750610/ /pubmed/36626539 http://dx.doi.org/10.1097/MD.0000000000032150 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 4500 Yoshikawa-Kimura, Akie Taira, Koichi Maruyama, Hirotsugu Ishikawa-Kakiya, Yuki Yamamura, Masafumi Tanoue, Kojiro Hagihara, Atsushi Uchida-Kobayashi, Sawako Enomoto, Masaru Kimura, Kenjiro Tanaka, Shogo Amano, Ryosuke Takemura, Shigekazu Ohfuji, Satoko Tanaka, Fumio Nagami, Yasuaki Fujiwara, Yasuhiro Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title | Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title_full | Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title_fullStr | Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title_full_unstemmed | Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title_short | Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX |
title_sort | influence of a biliary stent in patients with advanced pancreatic cancer treated with modified folfirinox |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750610/ https://www.ncbi.nlm.nih.gov/pubmed/36626539 http://dx.doi.org/10.1097/MD.0000000000032150 |
work_keys_str_mv | AT yoshikawakimuraakie influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT tairakoichi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT maruyamahirotsugu influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT ishikawakakiyayuki influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT yamamuramasafumi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT tanouekojiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT hagiharaatsushi influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT uchidakobayashisawako influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT enomotomasaru influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT kimurakenjiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT tanakashogo influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT amanoryosuke influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT takemurashigekazu influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT ohfujisatoko influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT tanakafumio influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT nagamiyasuaki influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox AT fujiwarayasuhiro influenceofabiliarystentinpatientswithadvancedpancreaticcancertreatedwithmodifiedfolfirinox |